Literature DB >> 21157470

Traumatic brain injury in mice lacking the K channel, TREK-1.

Khodadad Namiranian1, Christa D Brink, Jerry Clay Goodman, Claudia S Robertson, Robert M Bryan.   

Abstract

The purpose of this study was to determine whether the potassium channel, TREK-1, was neuroprotective after traumatic brain injury (TBI). Since there are no selective blockers, we used TREK-1 knockout (KO) mice for our study. Wild-type (WT) and TREK-1 KO mice were anesthetized and subjected to controlled-cortical impact injury (deformation of the brain by 1.5 mm by a 3-mm diameter rod traveling at a 3 m/s). Laser Doppler perfusion (LDP) decreased by ∼80% in the injured cortex and remained at that level in both WT and TREK-1 KO mice (n=10 and 11, respectively). Laser Doppler perfusion decreased by 50% to 60% in cortical areas directly adjacent to the site of injury. There were no statistical differences in LDP between genotype. The contusion volume, determined 15 days after the TBI using hematoxylin and eosin-stained coronal brain sections, was 4.1±0.8 (n=10) and 5.1±0.5 (n=11) mm(3) for WT and TREK-1 KO, respectively (not significant, P=0.34). Cell counts of viable neurons in the CA1 and CA3 regions of the hippocampus were similar between WT and TREK-1 KO mice (P=0.51 and 0.84 for CA1 and CA3, respectively). We conclude that TREK-1 expression does not provide brain protection after TBI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21157470      PMCID: PMC3063636          DOI: 10.1038/jcbfm.2010.223

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  28 in total

Review 1.  Homeostatic regulation of neuronal excitability by K(+) channels in normal and diseased brains.

Authors:  Hiroaki Misonou
Journal:  Neuroscientist       Date:  2010-02       Impact factor: 7.519

2.  Validation of a controlled cortical impact model of head injury in mice.

Authors:  H J Hannay; Z Feldman; P Phan; A Keyani; N Panwar; J C Goodman; C S Robertson
Journal:  J Neurotrauma       Date:  1999-11       Impact factor: 5.269

Review 3.  The neuronal background K2P channels: focus on TREK1.

Authors:  Eric Honoré
Journal:  Nat Rev Neurosci       Date:  2007-04       Impact factor: 34.870

Review 4.  Sodium and potassium channel modulators: their role in neuroprotection.

Authors:  T P Obrenovitch
Journal:  Int Rev Neurobiol       Date:  1997       Impact factor: 3.230

5.  Cerebrovascular responses in mice deficient in the potassium channel, TREK-1.

Authors:  Khodadad Namiranian; Eric E Lloyd; Randy F Crossland; Sean P Marrelli; George E Taffet; Anilkumar K Reddy; Craig J Hartley; Robert M Bryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-31       Impact factor: 3.619

6.  K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid beta-protein precursor genes and neuronal death in rat hippocampus.

Authors:  C Heurteaux; V Bertaina; C Widmann; M Lazdunski
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  Cloning, functional expression and brain localization of a novel unconventional outward rectifier K+ channel.

Authors:  M Fink; F Duprat; F Lesage; R Reyes; G Romey; C Heurteaux; M Lazdunski
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

8.  Co-treatment with riluzole, a neuroprotective drug, ameliorates the 3-acetylpyridine-induced neurotoxicity in cerebellar Purkinje neurones of rats: behavioural and electrophysiological evidence.

Authors:  Mahyar Janahmadi; Iran Goudarzi; Mohammad Reza Kaffashian; Gila Behzadi; Yaqub Fathollahi; Sohrab Hajizadeh
Journal:  Neurotoxicology       Date:  2009-03-05       Impact factor: 4.294

9.  Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel.

Authors:  Nicolas Blondeau; Olivier Pétrault; Stella Manta; Valérie Giordanengo; Pierre Gounon; Régis Bordet; Michel Lazdunski; Catherine Heurteaux
Journal:  Circ Res       Date:  2007-06-07       Impact factor: 17.367

10.  Arylbenzazepines are potent modulators for the delayed rectifier K+ channel: a potential mechanism for their neuroprotective effects.

Authors:  Xue-Qin Chen; Jing Zhang; John L Neumeyer; Guo-Zhang Jin; Guo-Yuan Hu; Ao Zhang; Xuechu Zhen
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

View more
  5 in total

Review 1.  Pulmonary epithelial barrier function: some new players and mechanisms.

Authors:  Kieran Brune; James Frank; Andreas Schwingshackl; James Finigan; Venkataramana K Sidhaye
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-01-30       Impact factor: 5.464

2.  Deficiency of the two-pore-domain potassium channel TREK-1 promotes hyperoxia-induced lung injury.

Authors:  Andreas Schwingshackl; Bin Teng; Patrudu Makena; Manik Ghosh; Scott E Sinclair; Charlean Luellen; Louisa Balasz; Cynthia Rovnaghi; Robert M Bryan; Eric E Lloyd; Elizabeth Fitzpatrick; Jordy S Saravia; Stephania A Cormier; Christopher M Waters
Journal:  Crit Care Med       Date:  2014-11       Impact factor: 7.598

3.  Activation of K(2)P channel-TREK1 mediates the neuroprotection induced by sevoflurane preconditioning.

Authors:  L Tong; M Cai; Y Huang; H Zhang; B Su; Z Li; H Dong
Journal:  Br J Anaesth       Date:  2013-10-22       Impact factor: 9.166

4.  Controlled Decompression Attenuates Compressive Injury following Traumatic Brain Injury via TREK-1-Mediated Inhibition of Necroptosis and Neuroinflammation.

Authors:  Tao Chen; Xiao Qian; Jie Zhu; Li-Kun Yang; Yu-Hai Wang
Journal:  Oxid Med Cell Longev       Date:  2021-11-08       Impact factor: 6.543

5.  Localization of Multi-Lamellar Vesicle Nanoparticles to Injured Brain Tissue in a Controlled Cortical Impact Injury Model of Traumatic Brain Injury in Rodents.

Authors:  Ricky Whitener; Jeremy J Henchir; Thomas A Miller; Emily Levy; Aubrienne Krysiewicz-Bell; Eliza S LaRovere Abrams; Shaun W Carlson; Naresh Menon; C Edward Dixon; Michael J Whalen; Claude J Rogers
Journal:  Neurotrauma Rep       Date:  2022-04-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.